Jazz Pharma Plc (JAZZ)
$111.20 0.00 (0.00%)
16:22 EDT JAZZ Stock Quote Delayed 30 Minutes
Previous Close $111.20
Market Cap 6.44B
PE Ratio 15.23
Volume (Avg. Vol.)
Day's Range 111.20 - 111.20
52-Week Range 86.88 - 154.24
Dividend & Yield N/A (N/A)
JAZZ Stock Predictions, Articles, and Jazz Pharma Plc News
- From InvestorPlace
- From the Web
History shows that not only is there an opportunity to buy during a crisis, but that the best performers are the small caps.
In this rocky environment, investors should get to know GARP stocks for growth and value. These five stocks offer the best of both worlds.
P/B ratio is a convenient tool to identify low-priced stocks that have high-growth prospects. Here are five stocks with low P/B ratios.
These five biotech stocks balance low valuation with high growth and a track record of profits.
Volatility across all categories of biotech stocks makes this present juncture an ideal time to consider picking up undervalued names.
This week, the ratings of 10 Pharmaceuticals stocks on Portfolio Grader are down. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Jazz Pharmaceuticals stock is hovering around breakeven after agreeing to acquire Celator (CPXX) for a 73% premium. Does the deal make sense?
A bunch of biotech stocks are knocking on the door of news that could prove to be very good or very bad.
While the rest of the market is enjoying a healthy start to the fall, biopharma stocks continue to lag. Here are 5 pharma stocks on sale now
Actavis (ACT) and Jazz Pharmaceuticals (JAZZ) reported outstanding Q3 earnings and are strong biotech stocks to buy.
Can we learn to thrive in the HFT/algo world of high speed trading? Here are some tips and ideas on how to copy in a fast moving market
Two of Jazz Pharmaceuticals' drugs are showing record growth, and the stock just keeps making new highs. Can it last?
These are the 10 fastest-growing companies in the world according to Fortune.
From The Street
Navellier RatingsPowered by Portfolio Grader